NCT02242799 - Dolutegravir Interactions With Artemisinin-based Combination Therapies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

MalariaHIV

Interventions

DRUG

Dolutegravir 50mg od

Dolutegravir 50mg once daily will be given either alone or in combination, as specified

DRUG

Artemether-lumefantrine combination

Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK

DRUG

Artesunate-amodiaquine

Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters

Trial Locations (1)

Unknown

Infectious Diseases Institute, Kampala